A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
NCT07768436
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Adenocarcinoma of the Breast
- Breast Cancer
- Triple Negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) · Commack, NY
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) · Harrison, NY
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities) · New York, NY
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities) · Uniondale, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.